Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.

@article{ShemaDidi2016PreventionOC,
  title={Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.},
  author={Lilach Shema-Didi and Batya I Kristal and Sarit Eizenberg and Nabil Marzuq and Majdy Sussan and Yulie Feldman-Idov and Pnina Ofir and Shaul Atar},
  journal={Nephrology},
  year={2016},
  volume={21 4},
  pages={295-300}
}
AIM Contrast-induced-nephropathy (CIN) is associated with poor outcomes, thus prevention of CIN may be of clinical value. Erythropoietin (EPO) has been shown to elicit tissue-protective effects in experimental models and in clinical studies of acute kidney injury. We therefore evaluated its effectiveness for prevention of CIN after coronary angiography (CA) ± percutaneous coronary intervention (PCI) in diabetic patients with chronic kidney disease. METHODS A prospective, randomized… CONTINUE READING
1 Citations
38 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury

  • C Quintavalle, FioreD, F DeMicco
  • Circulation
  • 2012

Similar Papers

Loading similar papers…